Celgene Corp (CELG) 93.27 $CELG
Final Glance: Biotechnology companies
AP - Thu Sep 18, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Midday Glance: Biotechnology companies
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
3 Best Stocks for Investing in Biotech
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 18, 7:35AM CDT
Few baskets are as hit-and-miss as biotech. The group is notoriously fickle and maddeningly volatile -- and for good reason. Whims and whispers tied to the latest clinical trial results can move biotech stocks in fits and starts, making them best...
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 17, 2:00PM CDT
FDA approvals, a positive FDA panel outcome and positive phase II data were the key highlights in the biotech sector last week.
Early Glance: Biotechnology companies
AP - Wed Sep 17, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Safety Worries Over Celgene's Experimental Crohn's Drug Overblown
at The Street - Wed Sep 17, 7:26AM CDT
The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.
Jim Cramer's 'Mad Money' Recap: Let's Hear It for the Bull
at The Street - Tue Sep 16, 7:20PM CDT
The markets can continue to rebound but only if a few other things go right, Cramer says.
Celgene (CELG) Crosses Pivot Point Resistance at $90.93
Comtex SmarTrend(R) - Tue Sep 16, 10:14AM CDT
Shares of Celgene (NASDAQ:CELG) have bullishly opened above the pivot of $89.58 today and have reached the first resistance level of $90.93. Investors may be interested in a cross of the next upside pivot targets of $92.41 and $95.24.
Stock Market News for September 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:10AM CDT
Benchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
Jim Cramer's 'Mad Money' Recap: Time to Make Room for Alibaba
at The Street - Mon Sep 15, 7:00PM CDT
The market is getting weird and the fast-growing, high-multiple stocks are getting clobbered, Cramer says.
'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
at The Street - Tue Sep 16, 4:00AM CDT
The trading panel discussed Chinese stocks, Apple's new phone and whether Darden shares are worth buying.
Look for Shares of Celgene to Potentially Rebound after Yesterday's 2.25% Sell Off
Comtex SmarTrend(R) - Mon Sep 15, 3:51PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $88.22 to a high of $91.05. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $90.72 on volume of 4.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq Falls Hard, But Apple Resilient On iPhone Orders
at Investor's Business Daily - Mon Sep 15, 1:55PM CDT
The Dow Jones industrial average and S&P 500 traded in a tight range Monday, but the Nasdaq took a beating as profit-taking hit several recent highfliers. The Nasdaq moved off lows but still fell 0.9%, hurt by weakness in Tesla Motors (TSLA). Shares...
Jim Cramer Answers Twitter (TWTR) Questions on Alibaba IPO, Yahoo! (YHOO), Apple (AAPL) and More
at The Street - Mon Sep 15, 11:47AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions from the floor of the New York Stock Exchange, and he first tackles the upcoming Alibaba IPO.
Final Glance: Biotechnology companies
AP - Thu Sep 18, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Midday Glance: Biotechnology companies
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
3 Best Stocks for Investing in Biotech
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 18, 7:35AM CDT
Few baskets are as hit-and-miss as biotech. The group is notoriously fickle and maddeningly volatile -- and for good reason. Whims and whispers tied to the latest clinical trial results can move biotech stocks in fits and starts, making them best...
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 17, 2:00PM CDT
FDA approvals, a positive FDA panel outcome and positive phase II data were the key highlights in the biotech sector last week.
Early Glance: Biotechnology companies
AP - Wed Sep 17, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Safety Worries Over Celgene's Experimental Crohn's Drug Overblown
at The Street - Wed Sep 17, 7:26AM CDT
The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.
Jim Cramer's 'Mad Money' Recap: Let's Hear It for the Bull
at The Street - Tue Sep 16, 7:20PM CDT
The markets can continue to rebound but only if a few other things go right, Cramer says.
Celgene (CELG) Crosses Pivot Point Resistance at $90.93
Comtex SmarTrend(R) - Tue Sep 16, 10:14AM CDT
Shares of Celgene (NASDAQ:CELG) have bullishly opened above the pivot of $89.58 today and have reached the first resistance level of $90.93. Investors may be interested in a cross of the next upside pivot targets of $92.41 and $95.24.
Stock Market News for September 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:10AM CDT
Benchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
Jim Cramer's 'Mad Money' Recap: Time to Make Room for Alibaba
at The Street - Mon Sep 15, 7:00PM CDT
The market is getting weird and the fast-growing, high-multiple stocks are getting clobbered, Cramer says.
'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
at The Street - Tue Sep 16, 4:00AM CDT
The trading panel discussed Chinese stocks, Apple's new phone and whether Darden shares are worth buying.
Look for Shares of Celgene to Potentially Rebound after Yesterday's 2.25% Sell Off
Comtex SmarTrend(R) - Mon Sep 15, 3:51PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $88.22 to a high of $91.05. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $90.72 on volume of 4.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq Falls Hard, But Apple Resilient On iPhone Orders
at Investor's Business Daily - Mon Sep 15, 1:55PM CDT
The Dow Jones industrial average and S&P 500 traded in a tight range Monday, but the Nasdaq took a beating as profit-taking hit several recent highfliers. The Nasdaq moved off lows but still fell 0.9%, hurt by weakness in Tesla Motors (TSLA). Shares...
Jim Cramer Answers Twitter (TWTR) Questions on Alibaba IPO, Yahoo! (YHOO), Apple (AAPL) and More
at The Street - Mon Sep 15, 11:47AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions from the floor of the New York Stock Exchange, and he first tackles the upcoming Alibaba IPO.
